Bio-Techne rebrands genome engineering as part of R&D Systems portfolio

By The Science Advisory Board staff writers

September 21, 2020 -- Bio-Techne has rebranded its cell and gene engineering product offer as part of its R&D Systems biotechnology brand.

The company's B-MoGen Biotechnologies portfolio of genome engineering services, good manufacturing practice therapeutic manufacturing services, and proprietary transposon-transposase gene transfer system, TcBuster, has been rebranded under R&D Systems.

As part of the rebranding, the B-MoGen Biotechnologies website will be retired. All service details and purchasing options will be maintained on the R&D Systems website. The consolidation will help the company provide customers with discovery-to-clinic cell and gene therapy solutions.


Copyright © 2020 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here